An observational study in Stroke, Sleep Apnea Syndrome (OSAS) and Insomnia, sponsored by Malin Eleonora av Kák Gustafsson, MD, PhD. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.
Sponsored by Malin Eleonora av Kák Gustafsson, MD, PhD · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 158 studies in Stroke with a site in Sweden — 30 open to participants now, 42 under way, 5 of them phase 3. Stroke · Sweden.
Among the 158 studies in Stroke with a site in Sweden, this one is the 19th largest by planned enrollment of the 35 observational ones that give a count, is one of 9 that started in 2026, is one of 35 observational ones, reaches primary completion later than 31 of the 41 other live ones, and was the 150th registered.
8,258 studies on the registry are indexed under Stroke; 2,055 are open to participants now.
Browse Stroke studies →30 of the 158 studies in Stroke with a site in Sweden are open now. Recruiting first, the newest first:
Uppsala University · Sites in Sweden
Ages 18+
Karolinska Institutet · Sites in Sweden
Ages 18+
Karolinska Institutet · Sites in Sweden, Finland
Ages 18+
Region Skane · Sites in Sweden, Finland
Ages 18+
Otto Bock Healthcare Products GmbH · Sites in Sweden
Ages 2+
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 1,415 Stroke studies recruiting now, 695 (49%) set no upper age limit and 280 (20%) stop at 75 or younger; 77 take children under 18; 195 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
158 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 32 · Phase 4 8
First in 1982; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 226 is above the median of 152 across 1,968 observational studies indexed under Stroke.
Median enrollment 200 across the 123 interventional studies, 230 across the 35 observational. Of the 102 that completed or were terminated, 29 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 158 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Malin Eleonora av Kák Gustafsson, MD, PhD as lead sponsor.
Malin Eleonora av Kák Gustafsson, MD, PhD has 1 study filed under Stroke — fewer than ten, so there is no comparison to draw.
12 of the studies in Stroke with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06696079Rahul RajRestarting Early Versus Later Anticoagulation for Chronic Subdural Hematoma With Atrial Fibrillation | 2026-12 |
| NCT07517120Norwegian School of Sport SciencesHome-Based Stroke Rehabilitation Using Enriched Environments (PEER-HOMEcare) | 2027-01-31 |
| NCT06429332Region SkaneInternational Care Bundle Evaluation in Cerebral Hemorrhage Research | 2027-03-01 |
| NCT06979050Göteborg UniversityEvaluation of the Ronnie Gardiner Method in Individuals With Stroke in Late Phase of Recovery | 2027-03-15 |
| NCT06811948Blekinge County Council HospitalSleep-Disordered Breathing in the Acute Phase After Stroke and Neuropsychiatric Outcomes | 2027-05-20 |
Add all 12 to your calendar (.ics) → With an account.
Among the 158 studies in Stroke with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims to map sleep disorders and their impact on the ability to engage in an active daily life among people who have had a stroke, with particular focus on how sleep apnea can be identified.
The study has the following objectives:
There is currently a lack of understanding regarding how common sleep disorders are after stroke and how extensive their impact is on physical and psychological conditions. This project will investigate how common sleep disorders are in connection with stroke and how they affect patients with stroke physically and psychologically, as well as their level of activity in everyday life.
The project will also examine how healthcare services could identify who should undergo an assessment for sleep apnea. Today, there are commercial health technology products that alert users to potential breathing problems during the night, but it is unclear whether the information a patient presents to their doctor, based on these commercial health technology products, should be included in the clinical assessment of sleep apnea risk.
The project will consecutively invite individuals with stroke from Skåne and Blekinge, Sweden. Three months after their stroke, participants will complete questionnaires, undergo actigraphy and wear a commercial health technology product in the form of a smartwatch for one week, as well as complete an overnight respiratory recording. Based on this, it will be possible to determine how many participants have a sleep disorder and how it has affected them, as well as which factors make it likely that an individual has sleep apnea.
Patients with stroke residing in the local referral area of Skåne University Hospital (SUS) or in the local referral area of the Department of Medicine at Blekinge Hospital Karlskrona.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with first-time ischemic stroke in Skåne and Blekinge, Sweden.
Occurrence of sleep apnea
Percent of participants with sleep apnea as assessed by Home Sleep Apnea Testing.
Time frame: Three months post-stroke.
Occurrence of insomnia
Percent of participants with insomnia.
Time frame: Three months post-stroke.
MoCA
MoCA (Montreal Cognitive Assessment) is a cognitive screening tool scored 0-30, where higher scores indicate better cognitive function; a score of 26 or above is considered normal, with an optional +1 point for individuals with ≤12 years of education.
Time frame: Twelve months post-stroke.
MoCA
MoCA (Montreal Cognitive Assessment) is a cognitive screening tool scored 0-30, where higher scores indicate better cognitive function; a score of 26 or above is considered normal, with an optional +1 point for individuals with ≤12 years of education.
Time frame: Three months post-stroke.
Occurrence of excessive daytime sleepiness
Percent of participants with excessive daytime sleepiness.
Time frame: Three months post-stroke.
Physical movement behavior
Amount of time spent in different postures and activities during 24 hours.
Time frame: One week of continuous accelerometer monitoring three months post-stroke.
Physical movement behavior
Amount of time spent in different postures and activities during 24 hours.
Time frame: One week of continuous accelerometer monitoring twelve months post-stroke.
HADS
HADS (Hospital Anxiety and Depression Scale) includes two subscales (anxiety and depression) scored 0-21 each. 0 indicates no symptoms, and 21 indicates the most severe symptoms.
Time frame: Three months post-stroke.
HADS
HADS (Hospital Anxiety and Depression Scale) includes two subscales (anxiety and depression) scored 0-21 each. 0 indicates no symptoms, and 21 indicates the most severe symptoms.
Time frame: Twelve months post-stroke.
FAS
FAS (Fatigue Assessment Scale) is scored 10-50. 10 indicates no fatigue, and 50 indicates the most severe fatigue.
Time frame: Three months post-stroke.
FAS
FAS (Fatigue Assessment Scale) is scored 10-50. 10 indicates no fatigue, and 50 indicates the most severe fatigue.
Time frame: Twelve months post-stroke.
EQ-5D
EQ-5D produces an index score ranging from \<0 to 1. 1 indicates full health, and lower values indicate worse health (with values below 0 representing health states considered worse than death).
Time frame: Three months post-stroke.
EQ-5D
EQ-5D produces an index score ranging from \<0 to 1. 1 indicates full health, and lower values indicate worse health (with values below 0 representing health states considered worse than death).
Time frame: Twelve months post-stroke.
Level of breathing difficulties
Patient-reported breathing difficulties based on information they obtained from their commercial digital health smartwatch.
Time frame: Three months post-stroke.
Hba1c
HbA1c (Hemoglobin A1c) mmol/mol. Represents the average amount of blood sugar attached to hemoglobin over the past two to three months
Time frame: Baseline.
Cholesterol
Serum cholesterol in mmol/L
Time frame: Baseline.
Creatinine
Serum creatinine in µmol/L.
Time frame: Basline.
Plan to share: Yes — De-identified individual participant data underlying the results reported in the published article. No directly identifiable information will be shared, and all data will be processed in accordance with the EU General Data Protection Regulation (GDPR).
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: Beginning after publication of the primary results and continuing for 5 years thereafter.
Access criteria: Qualified researchers affiliated with academic, clinical, or research institutions may request de-identified individual participant data underlying the results reported in the published article. Researchers may submit a reasonable request to the Principal Investigator, including a description of the proposed analysis and data protection measures. Data access will be granted upon approval of the request and completion of a data-sharing agreement.
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Oct 2028, 31 months after the start.
Of 835 non-industry observational studies under Stroke, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 92. This study's planned 31 months is below that.
Counting every sponsor, half of 897 studies reached it within 40 months; a quarter within 18 and three quarters within 85.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.